CAMBRIDGE, Mass. (AP) -- Drug developer Epizyme Inc. on Wednesday named Jason Rhodes to an additional post as president of the company.
Epizyme said Rhodes will remain its chief financial officer. Rhodes joined the company in March 2010 and became CFO in March 2013. He reports to Robert J. Gould, the chief executive officer who had previously also been president.
Epizyme went public in May, selling 5.1 million shares of stock for $15 per share. The stock has doubled in value since then, and rose 7 cents to $30.66 in morning trading Wednesday. They hit a high for the year of $31.07 on Monday.
- Investment & Company Information
- Jason Rhodes